Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ilera Therapeutics LLC is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution involves 1 distinct examiner and 1 distinct art unit. This concentration indicates that the company's current patent activity is focused on a single technical examination path within the biotechnology sector. For the applicant, this means that the 1 art unit involved will be the primary source of examination standards for these filings.
The busiest examiner for this portfolio is CAIN, JENNIFER LYNN, who has 1 pending office action. This 1 action accounts for the entirety of the company's pending office actions. With 1 distinct examiner assigned to 1 pending action, the prosecution responsibility is centralized, requiring coordination with only one specific individual at the patent office. This 1 busiest examiner pending action represents the full extent of the company's current workload under review, allowing for a highly focused prosecution strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CAIN, JENNIFER LYNN | 1 | 43.5% | +67.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18988155 | ENHANCED CAPTURE AND DISSOLUTION MATRIX FOR CANNABINOIDS AND METHODS OF MAKING THE SAME | CAIN, JENNIFER LYNN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18988155 | ENHANCED CAPTURE AND DISSOLUTION MATRIX FOR CANNABINOIDS AND METHODS OF MAKING THE SAME | CAIN, JENNIFER LYNN | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18988155 | ENHANCED CAPTURE AND DISSOLUTION MATRIX FOR CANNABINOIDS AND METHODS OF MAKING THE SAME | CAIN, JENNIFER LYNN | 1655 | §102§112 | Non-Final OA | — | Pending | Dec 19, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIlera Therapeutics LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jennifer Lynn Cain has the most, with 1 of Ilera Therapeutics LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.